Upharmacia December 2017
PHARMA MARKET NEWS
Farmak Expects Increase of Retail
Sales by 18 % in
2018
Ukraine ’ s leading pharmaceutical company Farmak expects the sales of its drugs to rise by 18 % y-o-y in UAH in 2018 , the company ’ s Marketing Director Susanna Halilova stated . Herewith , the forecast on sales in volumes is unclear .
Farmak anticipates the medical reform to have impact on pharmaceutical market with regard to the changes in the sales structure of certain groups of drugs .
According to the forecast of Business Credit analytical company , the retail sales of Ukrainian drugs may increase 4 % in volumes and 10 % in values .
Yuria-Pharm may Supply
TB Drugs to Brazil
Ukrainian company Yuria-Pharm considers the possibility to supply its antitubercular drugs to Brazil , the company ’ s Director Dmytro Derkach said . Currently , the company is waiting for the results of the inspection conducted by the Brazilian regulatory body ( ANVISA ) in Nov .
“ Brazil is interested in Yuria-Pharm ’ s production , in particular , in its antitubercular drugs ,” Mr . Derkach stated .
In 2018 , Yuria-Pharm plans to continue implementing production of new drugs and
entering new external markets . Now , the company ’ s products are represented in 25 countries .
In 9M2017 , Yuria-Pharm was a # 1 supplier on the Ukrainian hospital drug market with 10 % market share . On the retail drug market , the company held 10th position .
Biofarma to Open a Blood Plasma Fractionation Plant in 2018
Ukrainian producer of blood preparations Biofarma plans to launch a blood plasma fractionation plant in Jul 2018 . The plant ’ s construction will cost USD 35 mio . Its capacity is to amount 500 tons of blood plasma .
“ We have an ambition to become a TOP-7 producer of blood plasma in the world ”, Biofarma ’ s President Konstantin Efimenko stated .
Biofarma produces more than 20 immunobiological preparations from donor blood obtained according to technology of recombinant DNA and probiotics . In 2014 , the company constructed its new plant in Bila Tserkva , investing about USD 42 mio .
Interchem Launched new
API Production Complex
Ukrainian company Interchem launched a new production complex for the production of Active Pharmaceutical Ingredients ( API ) at its plant in Odessa .
Completion of the complex construction has become the last phase within an investment project worth EUR 50 mio , which had been started in 2012 . About EUR 9 mio were invested in the construction of the complex .
Interchem also implemented a new drug labeling system used to automatically track the movement of drugs from the manufacturer to the end user or patient . The system uses two-dimensional codes of the GS1 ECC200 standard and was developed with recommendations of the European Federation of Pharmaceutical Industries and associations ( EFPIA ).
“ Counterfeit drugs are a serious problem in Ukraine ”, the Director of Interchem Anatoliy Reder said . “ As a single company in Ukraine , which implemented such system , Interchem participates in the pilot project of the State Service on Drug Control , aimed to addressing the problem through tracking the drugs turnover .”
Interchem is a full-cycle enterprise , which produces above 100 forms of drugs . In 2016 , Interchem was a 25th company on Ukrainian drug market by sales in values . In Dec , the company celebrated its 25th anniversary .
Indian Companies Plan to Increase Exports to Ukraine
to USD 300 mio in
2018
Indian Pharmaceutical Manufacturers Association ( IPMA ) stated that in 2016 exports to
6 www . upharma-c . com